Immune checkpoint blockade alone or in combination with targeted therapies has emerged as a promising intervention in patients with recurrent endometrial cancer in view of a high mutational burden (dMMR/POLEmut subtypes), tumour-infiltrating lymphocytes and programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) expression. This evidence concerns the gene CD274 and endometrial cancer.